EGFR and lung cancer: Opportunistically suppressing AKR1B1 with the selective inhibitor epalrestat (an antidiabetic drug) recovers the sensitivity of resistant cell lines to EGFR TKIs and delays resistance in lung cancer patient-derived xenograft mice.